SEC Form 4 · accession 0001077183-19-000035
NEOGENOMICS INC · NEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J. Shovlin
Officer — President, Clinical Services
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001077183
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2019 | A | 10,944 | $0.00 | A | 148,321 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.60 | Mar 1, 2019 | A | 66,897 | A | Mar 1, 2020 | Mar 1, 2024 | Common Stock | 66,897 | 66,897 | D |
| Stock Option (Right to Buy)F2 | $8.03 | holding | — | — | — | Feb 26, 2019 | Feb 26, 2023 | Common Stock | 288,500 | 288,500 | D |
| Stock Option (Right to Buy)F3 | $7.52 | holding | — | — | — | Apr 28, 2018 | Apr 28, 2022 | Common Stock | 133,334 | 133,334 | D |
| Stock Option (Right to Buy)F4 | $7.15 | holding | — | — | — | Apr 20, 2017 | Apr 20, 2021 | Common Stock | 66,666 | 66,666 | D |
Explanation of responses
- F1On March 1, 2019, Mr. Shovlin was granted an option to purchase 66,897 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date.
- F2On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vest ratably over the first three anniversary dates of the grant date.
- F3On April 28, 2017, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.
- F4On April 20, 2016, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.